The BIOSECURE Act, now part of the NDAA, will put in motion US government-wide restrictions on ‘biotechnology companies of concern’.

Prior to last month’s series of mass layoffs in Maryland, Catalent was issued two Form 483s for its gene therapy facilities in the state, which

We’re a bit less than a month out from the JP Morgan meeting, where we’ll host our own event on Monday and Tuesday that week

This is our final Peer Review in 2025. Thank you for reading the latest comings and goings for another year. Enjoy the holidays, and we’ll

Pharma marketers enter 2026 asking where DTC fits in the DTP era. That question, which few foresaw 12 months ago, reflects the fast rise of